Related by context. Frequent words. (Click for all words.) 90 Completes Enrollment 88 Presents Positive 85 Initiates Phase 85 Drug Candidate 84 Clinical Trial Results 84 Patient Enrollment 83 FDA Accepts 83 Phase III Clinical Trial 83 FDA Clears 83 Pivotal Phase III 83 Initiate Phase 82 Pivotal Phase 82 Phase III Trial 81 Receives FDA Clearance 81 Announces Initiation 81 Preclinical Data 80 Inc Therapeutic Competitors 80 Announces Publication 79 Announces Presentation 79 Pivotal Trial 78 FDA Approves 78 Patent Covering 77 Reports Positive 77 Files Shelf Registration Statement 77 Announces Positive 77 Study Demonstrates 77 Shows Promise 77 II Clinical Trial 77 Generic Version 77 Reduces Risk 76 Small Molecule 76 Announces Successful Completion 76 Patent Issued 76 Significantly Reduces 76 Receives Patent 75 Q1 Loss Narrows 75 Metastatic Melanoma 75 Q2 Loss Narrows 75 Recombinant Human 75 Q3 Loss Narrows 75 Q3 Loss Widens 75 Cholesterol Drug 75 Q4 Loss Narrows 75 Well Tolerated 75 refractory chronic lymphocytic 75 Achieves Milestone 74 Chronic Hepatitis C 74 Patients Treated 74 Q2 Loss Widens 74 Monoclonal Antibody 74 Receives Positive 74 MKC# 74 Q4 Loss Widens 74 Awarded Patent 73 Announces Issuance 73 Metastatic Colorectal Cancer 73 Significantly Increases 73 Completes Tender Offer 73 RNAi Therapeutics 73 J Am Coll 73 Pulmonary Arterial Hypertension 73 Announces Stockholder Approval 73 Receives CE 73 Inc. Nasdaq IMGN 73 Q1 Loss Widens 73 Regains Compliance 73 Announces Immediate Availability 73 Prostate Cancer Patients 73 Monotherapy 73 Signs Licensing Agreement 73 Updates Guidance 73 Low Dose 72 Acquires Exclusive 72 Successful Completion 72 Net Loss Narrows 72 Transcept Pharmaceuticals 72 Regains Compliance With 72 Positive Opinion 72 Elderly Patients 72 Combination Therapy 72 Benign Prostatic Hyperplasia 72 Panzem R 72 FDA Clearance 72 Anti Inflammatory 72 Explore Strategic Alternatives 72 Net Loss Widens 72 Blood Thinner 72 Announce Collaboration 72 Heart Failure Patients 72 CHEAP ONLINE PHARMACY LOW 72 Increases Risk 72 Provides Guidance 72 Drug Resistant 72 J Am Acad 71 Patients Undergoing 71 Inhibits 71 submitted Biologics License 71 Vertex Pharmaceuticals Announces 71 Postmenopausal Women 71 Kuvan R 71 Introduces Next Generation